Non-small Cell Lung Cancer
Conditions
Keywords
non-small cell lung cancer (NSCLC), NFE2L2, NRF2, KEAP1, CUL3, MGY825
Brief summary
Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer.
Detailed description
First in human, phase I, multicenter, open-label study of MGY825 single agent with a dose escalation and a dose expansion in adult patients with advanced non-small cell lung cancer (NSCLC). The dose escalation part investigated the safety and tolerability of MGY825 in adult patients with advanced NSCLC harboring NFE2L2, or KEAP1 or CUL3 (NFE2L2/KEAP1/CUL3) mutations. Patient enrollment was based on locally available test results of mutation status. An exploratory assessment on the effect of food could be investigated during the dose escalation part. The dose expansion part assessed the preliminary anti-tumor activity and further assess the safety and tolerability of MGY825 in adult patients with advanced NSCLC divided in two patient groups. Group 1: Patients with advanced NSCLC harboring NFE2L2/KEAP1/CUL3 mutations enrolled based on locally available test results of mutation status. Group 2: Patients with advanced NSCLC irrespective of prior knowledge of NFE2L2/KEAP1/CUL3 mutational status.
Interventions
DRUGMGY825
investigational drug
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Signed informed consent must be obtained prior to participation in the study. * Dose escalation and dose expansion group 1: Patients with histologically or cytologically confirmed diagnosis of advanced (metastatic or unresectable) NFE2L2/KEAP1/CUL3 mutant NSCLC. Local data confirming the NFE2L2/KEAP1/CUL3 mutation status in tissue must be available for enrollment. * Dose expansion group 2: Patients with histologically or cytologically confirmed diagnosis of advanced (metastatic or unresectable) NSCLC irrespective of NFE2L2/KEAP1/CUL3 mutation status. * All patients: Patients must have progressed after 1 platinum-based chemotherapy regimen and PD-(L)1 antibody therapy either sequentially or concurrent with chemotherapy, where indicated, for Stage IV NSCLC. Patients treated with neo-adjuvant / adjuvant platinum-based therapy that progressed within 6 months of treatment are permitted to participate. Prior therapy with VEGF/VEGFR targeting agents is permitted. Prior treatment with approved targeted drugs (e.g., EGFRi, ALKi, METi) is mandatory in patients with NSCLC whose tumor bears actionable mutations. * Presence of at least one measurable lesion according to RECIST v1.1. * Patient must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening and during study treatment. A recent biopsy collected after the last systemic treatment and within 3 months before study entry may be submitted at screening.
Exclusion criteria
* Having out of range laboratory values defined as: Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) \< 60 mL/min Total bilirubin \> 1.5 x ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin \> 3.0 x ULN or direct bilirubin \> 1.5 x ULN ALT \> 3 x ULN AST \> 3 x ULN ANC \< 1.0 x 109/L Platelet count \< 75 x 109/L Hemoglobin \< 9 g/dL * Impaired cardiac function or clinically significant cardiac disease, including any of the following: Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment (NYHA Grade ≥2), uncontrolled hypertension or clinically significant arrhythmia. QTcF \> 470 msec on screening ECG or congenital long QT syndrome. Acute myocardial infarction or unstable angina pectoris \< 3 months prior to study entry. * Presence of symptomatic CNS metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery) or increasing doses of corticosteroids within 2 weeks prior to study entry. Patients with treated symptomatic brain metastases should be neurologically stable (for 4 weeks post-treatment and prior to study entry) and at a dose of ≤ 10 mg per day prednisone or equivalent for at least 2 weeks before administration of any study treatment. * Known active COVID-19 infection. * Unable or unwilling to swallow capsules as per dosing schedule. Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and nature of dose limiting toxicities (DLTs) during the first 28 days of treatment with the study drug | 28 days | A DLT is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥3 assessed as not primarily related to disease, disease progression, inter-current illness or concomitant medications that occurs during the first 28 days of treatment with the study drug. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher. |
| Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) | 28 months | Assessment of safety of study drug as a single agent |
| Frequency of dose interruptions and reductions | 28 months | Assessment of tolerability of study drug as a single agent |
| Dose intensity | 28 months | Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of exposure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Peak concentration (Cmax) | 20 months | Pharmacokinetics (PK) parameters will be determined by non-compartmental methods using the PK profile of the study drug. |
| Duration of response (DOR) per RECIST 1.1 | 28 months | Evaluation of preliminary anti-tumor activity of study drug as single agent |
| Progression free survival (PFS) per RECIST 1.1 | 28 months | Evaluation of preliminary anti-tumor activity of study drug as single agent |
| Time to reach maximum drug concentrations in systemic circulation (Tmax) | 20 months | Pharmacokinetics (PK) parameters will be determined by non-compartmental methods using the PK profile of the study drug. |
| Overall response rate (ORR) per RECIST 1.1 | 28 months | Evaluation of preliminary anti-tumor activity of study drug as single agent |
| Area under the concentration-time curve (AUC) | 20 months | Pharmacokinetics (PK) parameters will be determined by non-compartmental methods using the PK profile of the study drug. |
Countries
Germany, Japan, South Korea, Spain, Switzerland, United States
Outcome results
None listed